home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

299 rows where filing_period = "third_quarter", filing_year = 2022 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 299 ✖

filing_year 1

  • 2022 · 299 ✖

filing_period 1

  • third_quarter · 299 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2859704 CPPI, CO. 4e52ff68-c95e-4b9a-afe2-47a05633b422 Q3 CPPI, CO. 401106160 CPPI, CO. 2022 third_quarter PHA Advocate in support of personal prescription drug importation from Canada, particularly in the Safe and Affordable Drugs from Canada Act of 2021 (S.259/H.R.832) and the Affordable and Safe Prescription Drug Importation Act (S.920/H.R.2181). HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-10-01T14:46:35-04:00
2859934 AMERICAN PHARMACISTS ASSOCIATION ab69e99a-3b41-4f82-901d-8313177abf42 Q3 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2022 third_quarter PHA H.R. 7213 - To amend title XVIII of the Social Security Act to provide pharmacy reimbursement for COVID-19-related and future emergency services. S 4293 - Pharmacy Benefit Manager Transparency Act of 2022 HOUSE OF REPRESENTATIVES,SENATE   35000 0 0 2022-10-03T11:20:42-04:00
2860083 RAY ANDERSON dd5226f0-7868-4422-930b-72237075335a Q3 RAY ANDERSON 401105487 340B HEALTH 2022 third_quarter PHA Requesting the Secretary of Health and Human Services and HRSA to enforce a statute ordering drug companies to restore 340B discounts to contract pharmacies Requesting Centers for Medicare and Medicaid Services to restore the Medicare hospital Outpatient Prospective Payment System reimbursement rate Requested Representative Spanberger and Representative Danny K. Davis and members of the Congressional Black Caucus participation in a Congressional Special Order Hour session. Gathered CBC member signatures on a Dear Colleague request to Secretary of HHS Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA) 15000   0 0 2022-10-03T20:23:40-04:00
2860085 RAY ANDERSON 463783cc-2dbf-4cab-a3d5-fcda7523925a Q3 RAY ANDERSON 401105487 340B HEALTH 2022 third_quarter PHA Requesting the Secretary of Health and Human Services and HRSA to enforce a statute ordering drug companies to restore 340B discounts to contract pharmacies Requesting Centers for Medicare and Medicaid Services to restore the Medicare hospital Outpatient Prospective Payment System reimbursement rate Requested Representative Spanberger and Representative Danny K. Davis and members of the Congressional Black Caucus participation in a Congressional Special Order Hour session. Gathered CBC member signatures on a Dear Colleague request to Secretary of HHS Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA) 15000   0 0 2022-10-03T20:23:53-04:00
2860137 AMERICAN COLLEGE OF CLINICAL PHARMACY 62ce50dd-af45-4867-bc35-a83ba596694e Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2022 third_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2022-10-04T10:17:24-04:00
2860598 BUCHANAN INGERSOLL & ROONEY PC 61149c45-4c8c-41a2-823d-c30e9b4aeba9 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2022 third_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. FY 2023 Appropriations for Defense Department, and National Institutes of Health (NIH). Work with Department of Defense on Ebola countermeasures. Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Navy, Dept of,SENATE 20000   0 0 2022-10-05T10:18:09-04:00
2860981 EQV STRATEGIC 5433ba6f-5b92-400f-aa62-87d1253795e2 Q3 EQV STRATEGIC 401105663 BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. 2022 third_quarter PHA Vaccine Development Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2022-10-06T09:12:32-04:00
2861107 MCDERMOTT+ LLC c8347bfd-1b1c-4af5-811e-a8abb980e7f4 Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2022 third_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program, including the Closing Loopholes for Orphan Drugs Act (H.R. 853). HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2022-10-06T14:25:04-04:00
2861123 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 92242fc4-0668-43b8-80a6-4f6d8c844b46 Q3 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2022 third_quarter PHA COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2022-10-06T15:21:57-04:00
2861519 RED+BLUE STRATEGIES 059eb52b-fb9a-442c-a2e9-1f85eb811139 Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2022 third_quarter PHA PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule. S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain. S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work. S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule. S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans. Issues and legislative vehicles related to capping the price of Insulin. Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR). H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule. PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2022-10-08T09:40:46-04:00
2861528 RED+BLUE STRATEGIES dbeab2da-c961-475c-8ff5-f24b88983eb6 Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2022 third_quarter PHA PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program. S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-10-08T10:30:52-04:00
2862094 PENN AVENUE PARTNERS f6a94a7d-a614-4c2e-b3a9-32b8e713bdac Q3 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2022 third_quarter PHA Regulatory and legislative issues impacting Alkermes. S.3593 - Telehealth Extension and Evaluation Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-10-10T21:26:28-04:00
2862153 PENN AVENUE PARTNERS aa7cfdf9-d0d2-4615-b431-e39951ba0ea8 Q3 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2022 third_quarter PHA Pharmacy benefit related issues. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2022-10-11T08:44:43-04:00
2862271 POLSINELLI PC 432ab28c-fbc2-49e4-b87c-28ad393e973a Q3 POLSINELLI PC 314911 TEVA PHARMACEUTICALS USA, INC. 2022 third_quarter PHA Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-10-11T11:21:42-04:00
2862398 PARDES BIOSCIENCES, INC. 1df8a59f-dd4c-4868-baa4-7581c5ff3878 Q3 PARDES BIOSCIENCES, INC. 401106493 PARDES BIOSCIENCES, INC. 2022 third_quarter PHA Covid Oral Anti Virals Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE   120000 0 0 2022-10-11T13:27:31-04:00
2862638 BROWN & FORTUNATO, P.C. 4445d393-c127-46ce-85f6-897e4be983ea Q3 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2022 third_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators. Centers For Medicare and Medicaid Services (CMS) 20000   0 0 2022-10-11T16:13:59-04:00
2862886 HOLLAND & KNIGHT LLP 50fa673b-27cb-41a4-9fbf-b2499e6274cb Q3 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2022 third_quarter PHA Drug shortages, formulary tiering, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021 (H.R. 2846), biosimilar uptake, Medicare generics penalty, generic drugs issues, supply chain issues, e-labeling provision in the FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill (H.R. 4356), and Military Construction, Veterans Affairs, and Related Agencies appropriations bill (H.R. 4355), Prescription Drug Pricing Dashboard Act (S. 1773); drug pricing; Build Back Better Act (H.R. 5376); Enhanced Access to Affordable Medicines Act of 2022 (H.R. 6973); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032); Generic Drug User Fee Amendments. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-12T08:06:21-04:00
2863035 HUMANITY FORWARD 0359ecf0-e4de-4d93-9250-cece2b638b67 Q3 HUMANITY FORWARD 401105867 HUMANITY FORWARD 2022 third_quarter PHA Issues and legislation related to reduction of prescription medication for Americans HOUSE OF REPRESENTATIVES,SENATE   250000 0 0 2022-10-12T10:59:02-04:00
2863105 WATKINS & EAGER PLLC 65b54951-9914-4218-8487-0401afd05d4b Q3 WATKINS & EAGER PLLC 401104403 ZYNERBA PHARMACEUTICALS, INC. 2022 third_quarter PHA Providing services on behalf of Zynerba to the pharmaceutical industry - looking for testing sites HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2022-10-12T11:19:42-04:00
2863312 INDEPENDENT PHARMACY COOPERATIVE 8ac64f93-f5d0-42ae-a2af-ca076df99907 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2022 third_quarter PHA IPC supports The Pharmacy Benefit Manager Transparency Act of 2022 IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing IPC supports FTC investigation into vertical PBM arrangements IPC is against decreased pharmacy reimbursement in the TRICARE program IPC is neutral and sought clarifications on the drug pricing provisions of the Inflation Reduction Act of 2022. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office   30000 0 0 2022-10-12T14:22:59-04:00
2863463 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH bd1ee63c-91ea-4877-981a-28fa1c83b56f Q3 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2022 third_quarter PHA General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act H.R. 5376, the Inflation Reduction Act of 2022 Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   31190 0 0 2022-10-12T16:17:58-04:00
2863528 BOLD STRATEGIES, LLC e267c8e8-5487-4d40-98e4-d0854dadbd16 Q3 BOLD STRATEGIES, LLC 401104653 MORRIS & DICKSON CO., LLC 2022 third_quarter PHA Prescription drug issues generally. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2022-10-12T16:50:13-04:00
2863621 DAVE KOLBE CONSULTING 642f3704-2a82-4f5f-acab-0f1f052cb1a2 Q3 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2022 third_quarter PHA Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization. Waiver of Certain Obligations under the WTO Agreement on Trade Related Aspects of Intellectual Property Rights for COVID-19 to also cover Therapeutics and Diagnostics. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-10-12T19:08:42-04:00
2864065 UNIVERSITY OF IOWA 17e68856-43c8-453c-b5b9-740e99eafd7e Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2022 third_quarter PHA N/A HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2022-10-13T12:13:40-04:00
2864201 NELSON MULLINS RILEY & SCARBOROUGH a53d0e2b-1d8d-4b86-8792-65aec052259a Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2022 third_quarter PHA 340B Drug Pricing Program, patient co-pay policies HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-10-13T14:10:18-04:00
2864307 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 9adc5de9-8c5c-4297-aae0-35132e4a7065 Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2022 third_quarter PHA S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office   400000 0 0 2022-10-13T15:10:45-04:00
2864399 NELSON MULLINS RILEY & SCARBOROUGH 9559bc11-2500-45ff-9907-5976693491e0 Q3 NELSON MULLINS RILEY & SCARBOROUGH 285871 TIDELANDS HEALTH 2022 third_quarter PHA Issues related to the 340B drug pricing program HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-10-13T15:56:55-04:00
2864566 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 86512a57-1bfd-4969-a2f6-8b7edb42787e Q3 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2022 third_quarter PHA Any bill(s), provision(s), or action(s) impacting the 340B Drug Discount Program and hospitals and health systems ability to provide access to these drugs for patients. S.773 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. Any bill(s) or provision(s) addressing high drug prices. HOUSE OF REPRESENTATIVES,SENATE   122772 0 0 2022-10-13T17:18:19-04:00
2865039 REPUBLIC CONSULTING, LLC 2d873da6-d539-4e0b-82e4-953540de0686 Q3 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2022 third_quarter PHA Monitored Health Data Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-14T11:22:32-04:00
2865109 STONINGTON GLOBAL 83b5ea3b-4d30-43ad-aa1d-2d7c676038c4 Q3 STONINGTON GLOBAL 401105189 SORRENTO THERAPEUTICS, INC. 2022 third_quarter PHA Regulatory approvals and funding for pharmaceutical products and devices Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 150000   0 0 2022-10-14T11:47:11-04:00
2865289 DESIMONE CONSULTING, LLC c3994e5a-ca36-4017-8a4a-c5870053eb40 Q3 DESIMONE CONSULTING, LLC 400931695 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2022 third_quarter PHA Issues related to patient access and pricing; Issues related to policy changes to Medicare Part D; Issues related to PBM reform; PDUFA Reauthorization, H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; FY2022 Budget Reconciliation (H.R.5376); H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-14T12:52:26-04:00
2865298 CORNERSTONE GOVERNMENT AFFAIRS, INC. f1145758-ca4c-4372-a79e-04977b538c61 Q3 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2022 third_quarter PHA Representation on health-related issues including reimbursement, research, public-health & clinical care Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2022-10-14T12:54:56-04:00
2865412 MLJ STRATEGIES fb264656-2931-4604-9feb-6cfa58ddcfe8 Q3 MLJ STRATEGIES 401105126 ANKURA CONSULTING GROUP, LLC ON BEHALF OF ON DEMAND PHARMACEUTICALS 2022 third_quarter PHA Advocating on issues related to pharmaceutical appropriations HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-10-14T13:25:14-04:00
2865421 MLJ STRATEGIES 0598a19f-b57a-444b-bf9e-ca6ef10f0b14 Q3 MLJ STRATEGIES 401105126 ANKURA CONSULTING GROUP, LLC ON BEHALF OF THORNE RESEARCH 2022 third_quarter PHA Advocate on issues related to supplement use in the military HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-10-14T13:28:47-04:00
2865430 HOGAN LOVELLS US LLP 7ea02c44-a958-4a18-9181-3bf2c7e26716 Q3 HOGAN LOVELLS US LLP 18422 ALVOGEN, PHARMA US, INC. 2022 third_quarter PHA Issues related to COVID-19 HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-10-14T13:35:05-04:00
2865607 KOUNTOUPES DENHAM CARR & REID, LLC 860e4f71-6a60-4f85-a9b4-430854008e4a 3T KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2022 third_quarter PHA Issues related to affordability, essential medicine manufacturing, and pharmaceuticals. General issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to the Inflation Reduction Act (Public Law 117-169), focusing on pharmaceutical provisions. HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2022-10-14T14:46:39-04:00
2865807 LUNGREN LOPINA LLC 96db87e4-6bca-47ca-a57e-21f2625747a4 Q3 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2022 third_quarter PHA Fair treatment for US based pharmaceutical ingredients HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-10-14T15:32:56-04:00
2866137 CORNERSTONE GOVERNMENT AFFAIRS, INC. 9b9c251a-af82-4f1b-8d76-d92d0181a33b 3T CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 VYRIPHARM ENTERPRISES, INC. 2022 third_quarter PHA Policies and regulations associated with testing, tracing and tracking of cannabinoids. HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE     0 1 2022-10-14T22:34:31-04:00
2866151 ALB SOLUTIONS 9ca7defd-fc59-40d6-ada9-91050e272b3a Q3 ALB SOLUTIONS 401105973 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2022 third_quarter PHA Issues related to regulatory and legislative developments regarding biosimilars. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-10-15T08:19:38-04:00
2866416 ISEMAN & ASSOCIATES LLC aeced5fc-fe24-442a-878b-518cadf57164 Q3 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2022 third_quarter PHA Monitoring biotech legislation; prescription drug prices; COVID- Relief legislation; Infrastructure Legislation; FY22 Appropriations bills HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2022-10-15T14:57:51-04:00
2866925 AMERICAN VETERINARY MEDICAL ASSOCIATION 68e1ec83-88d0-47f0-be87-365d3d88f791 Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2022 third_quarter PHA Review of Food and Drug Administrations Final Guidance for industry #256: Compounding Animal Drugs from Bulk Drug Substances Review of Food and Drug Administrations Animal Generic Drug User Fee Act Reports Compounding Guidance (GFI 256) Animal Drug Fee Act/Animal Generic Drug User Fee Act reauthorization HOUSE OF REPRESENTATIVES,SENATE 300000   0 0 2022-10-17T08:28:12-04:00
2867049 THE CONSILIO GROUP 9d868664-cffb-49a8-b0be-8fef33180848 Q3 THE CONSILIO GROUP 400374717 PARATEK PHARMACEUTICALS 2022 third_quarter PHA Paratek is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use. Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office 24000   0 0 2022-10-17T09:39:03-04:00
2867383 BLUESTONE STRATEGIES, LLC 8b0d18c6-7ec9-4d53-ab5d-ecdf205ab4bf Q3 BLUESTONE STRATEGIES, LLC 400658980 AMERICA'S HEALTH INSURANCE PLANS (AHIP) 2022 third_quarter PHA HR 3, Lower Drug Costs Now Act; HR 5260, Reduced Cost and Continued Care Act; Specialty Drugs and Prescription Drug Pricing, HR 19. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-17T11:08:08-04:00
2867414 BLUESTONE STRATEGIES, LLC 2d84e5ab-64ae-4b65-a296-20bf410fffb1 Q3 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2022 third_quarter PHA Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-17T11:12:40-04:00
2867421 RICCHETTI INCORPORATED 78a2c646-e6f0-49d2-9ac0-144ff65f7bca Q3 RICCHETTI INCORPORATED 62778 EISAI, INC. 2022 third_quarter PHA Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-10-17T11:15:06-04:00
2867477 RICCHETTI INCORPORATED 5f202dd2-5fc7-44e4-a61e-0b421c33aca0 Q3 RICCHETTI INCORPORATED 62778 HORIZON THERAPEUTICS USA INC 2022 third_quarter PHA Issues related to pharmaceutical industry, generally; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-10-17T11:23:15-04:00
2867497 RICCHETTI INCORPORATED a5aebe22-cc6f-4bd4-ac1c-368209ea5ce0 Q3 RICCHETTI INCORPORATED 62778 IPSEN BIOPHARMACEUTICALS, INC. 2022 third_quarter PHA Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-10-17T11:27:58-04:00
2867519 RICCHETTI INCORPORATED 06418cdf-dea2-4da3-8839-65125d010963 Q3 RICCHETTI INCORPORATED 62778 NEUROCRINE BIOSCIENCES, INC. 2022 third_quarter PHA Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-10-17T11:30:44-04:00
2867528 RICCHETTI INCORPORATED deb22d4f-057a-49ad-b3e7-723d3b607948 3T RICCHETTI INCORPORATED 62778 PARDES BIOSCIENCES, INC. 2022 third_quarter PHA Issues related to government involvement in the development of COVID-19 therapies HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2022-10-17T11:33:30-04:00
2867530 RICCHETTI INCORPORATED 9ae044a4-a1f1-4051-97ce-c636c40129ba Q3 RICCHETTI INCORPORATED 62778 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2022 third_quarter PHA Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-17T11:34:47-04:00
2867546 FORBES-TATE a249dbbb-734c-4ff7-a51a-30566e932037 Q3 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2022 third_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169). HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-10-17T11:37:51-04:00
2868006 CHRISTIANACARE 9e5e5525-3e4c-4754-90c4-80510423b720 Q3 CHRISTIANACARE 401105790 CHRISTIANACARE 2022 third_quarter PHA Specific lobbying issues: Issues related to the 340B Program, in general House(s) of Congress and Federal Agencies HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-10-17T13:13:17-04:00
2868310 FORBES-TATE e5aed995-078d-4877-8571-246aa852f00d Q3 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2022 third_quarter PHA Issues related to pharmacy regulation, the MAC Transparency Act, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-17T14:30:21-04:00
2868663 GOVERNMENT COUNSEL, LLC 2f570d0b-4357-42d5-ae61-3bb40545b4a0 Q3 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2022 third_quarter PHA General issues related to opioid medication assisted treatment. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-17T15:27:08-04:00
2868671 THE D MAJOR GROUP baf14b24-c641-4886-adc7-938857669cbc Q3 THE D MAJOR GROUP 401103162 EMD SERONO, INC. 2022 third_quarter PHA Monitor FDA User Fee Reauthorization measures as included in HR 6833, the "Continuing Appropriations & Ukraine Supplemental Appropriations Act." HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-10-17T15:29:25-04:00
2869246 OREGON HEALTH & SCIENCE UNIVERSITY 7f589831-3a8c-4d9f-ac1b-8e4fba9ad593 Q3 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2022 third_quarter PHA Support for the 340B Drug Discount Program for safety net hospitals and enforcing the Health Resources and Services Administration's statute governing the program. HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2022-10-17T17:22:54-04:00
2869290 WEST FRONT STRATEGIES LLC e2a75fd5-74af-414d-9d03-5b8796477631 Q3 WEST FRONT STRATEGIES LLC 401103493 VIATRIS INC 2022 third_quarter PHA Issues related to e-labeling; monitor issues related to Pharmacy Benefit Manager Transparency Act of 2022 (S.4293). HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2022-10-17T17:41:20-04:00
2869313 KNIGHT CAPITOL CONSULTANTS c19ebd7a-203f-4a56-aab0-8b794c28ca5a Q3 KNIGHT CAPITOL CONSULTANTS 40036301 REGENXBIO 2022 third_quarter PHA Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill) SENATE 60000   0 0 2022-10-17T17:55:53-04:00
2869509 BROYDRICK & ASSOCIATES c563b717-00ea-42f9-8dc2-fd66a814db78 Q3 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2022 third_quarter PHA Funding new drug for PTSD and COVID-19. BARDA appropriations. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-10-17T20:08:34-04:00
2869520 PORT SIDE STRATEGIES, LLC 80fcba75-5441-4dc2-89e2-b0c77fcd7245 Q3 PORT SIDE STRATEGIES, LLC 401105394 NEW VENTURE FUND 2022 third_quarter PHA H.R.8289 - Banning Misleading Drug Ads Act of 2022 - in support. HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-10-17T20:12:04-04:00
2869714 CAPITOL COUNSEL LLC b450a307-2abd-402f-a65b-ad1fcb8918e9 Q3 CAPITOL COUNSEL LLC 313715 EMD SERONO, INC. 2022 third_quarter PHA Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-10-17T21:58:36-04:00
2869849 ACG ADVOCACY b728ea23-bbb5-4148-951b-9ec263292387 Q3 ACG ADVOCACY 2057 WALGREEN CO. 2022 third_quarter PHA Drug Pricing Policy Issues. Data privacy and DIR fee reform. Counterfeiting Issues. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-10-18T02:08:48-04:00
2870180 PUBLIC CITIZEN f4bc27cb-ed05-458d-82b9-b05fc8a8e4b2 Q3 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2022 third_quarter PHA Drug price patent licensing executive action, INSULIN act, Licensing Government owned COVID technologies, Exercising executive licensing authorities to lower drug prices, HR 7900-NDAA amendment on Public protection of insulin for DOD, reconciliation drug price reform, and drug price negotiation provisions, Executive action to expand monkey pox Vaccine access, Global Covid 19 funding, HR 5376-Inflation reduction Act-drug pricing reform, insulin and drug price negotiation provisions, global and domestic monkey pox funding, Prescription Drugs affordability and access act, We PAID Act, USG support for mRNA hub HOUSE OF REPRESENTATIVES,SENATE,White House Office   70000 0 0 2022-10-18T10:10:22-04:00
2870673 PRIME POLICY GROUP 94c9d495-6eb5-4fbf-8b62-93be577a08fb Q3 PRIME POLICY GROUP 400532589 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2022 third_quarter PHA H.R. 7213 - Equitable Community Access to Pharmacist Services Act; Vaccines for Uninsured Adults Initiative HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-18T11:39:25-04:00
2870699 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER abe2ff51-a482-40ae-b132-5d636591f092 Q3 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2022 third_quarter PHA 340B, white bagging, PDUFA Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   32090 0 0 2022-10-18T11:42:02-04:00
2870861 ARENTFOX SCHIFF LLP fe8d01eb-f08a-42d1-90fa-7ce174a4518d Q3 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2022 third_quarter PHA Prescription drug pricing generally S. 4293 (Pharmacy Benefit Manager Transparency Act of 2022), regarding prescription drug pricing HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-10-18T12:11:35-04:00
2870918 KING & SPALDING LLP 5eceb23a-a362-42aa-8b98-74443299a88a Q3 KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2022 third_quarter PHA Advocacy on low income subsidy benefits HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-18T12:16:05-04:00
2871175 ELI LILLY AND COMPANY 9af693e1-c562-4b1d-a880-ad0d3fa9f356 Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2022 third_quarter PHA Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435) HOUSE OF REPRESENTATIVES,SENATE   1210000 0 0 2022-10-18T13:01:58-04:00
2871525 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 529f0521-b25f-477e-955c-50528aa1f85b Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2022 third_quarter PHA OTC switch process -- no bill number H.R. 6000 - 21st Century Cures 2.0 S.1435/HR 2873 - Affordable Prescriptions for Patients Act of 2021 H.R.4405 - Small Business FDA User Fee Adjustment Act of 2021 H.R. 7667 - Food and Drug Amendments of 2022 Dietary Supplement Reform -- no bill number Cosmetics Reform -- no bill number S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022 Genus vs. FDA Circuit Court Lobby Activity S. 4535 - Food and Drug Administration Simple Reauthorization Act of 2022 or the "FDASRA Act of 2022" H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   142000 0 0 2022-10-18T14:02:15-04:00
2871859 LINCOLN PARK GROUP L.L.C. ce4ba80b-6819-4da7-a33f-4c122284d93b Q3 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2022 third_quarter PHA Support for S. 920/H.R. 2181 - A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals and S. 259/H.R. 832 - Safe and Affordable Drugs from Canada Act; S. 3399/H.R. 6532 Domain Reform for Unlawful Drug Sellers Act; S. 3984, Stop Illegal Online Sales of Controlled Substances Act; and other issues related to personal drug importation. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-10-18T15:00:58-04:00
2872099 KOUNTOUPES DENHAM CARR & REID, LLC 3f8c27b2-5cef-444c-b1f8-e149c35b2551 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2022 third_quarter PHA Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in user fees legislation. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-18T15:25:45-04:00
2872129 SQUIRE PATTON BOGGS 85d18e51-2716-4e7f-8b6d-6fe3ed540339 Q3 SQUIRE PATTON BOGGS 30906 SK HYNIX AMERICA, INC. 2022 third_quarter PHA Monitor proposals and issues related to biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 170000   0 0 2022-10-18T15:29:34-04:00
2872153 KOUNTOUPES DENHAM CARR & REID, LLC 6df5a43e-f8ed-47af-9401-614f340a6d05 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2022 third_quarter PHA Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to Monkeypox vaccine and treatment distribution. Issues related to drug pricing in the Inflation Reduction Act (Public Law 117-169). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-18T15:33:04-04:00
2872188 DENTONS US LLP c248b367-d2ee-43c2-ac9d-f1487923b65b Q3 DENTONS US LLP 36105 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA 2022 third_quarter PHA Federal issues impacting workforce and innovation in the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-10-18T15:38:07-04:00
2872345 KOUNTOUPES DENHAM CARR & REID, LLC 7c520daf-77ff-4cb1-8f97-3c19fcd6e838 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2022 third_quarter PHA General issues related to over-the-counter pharmaceutical supply chain. Issues related to dietary supplements and cosmetic reform in the user fees reauthorization legislation.   50000   0 0 2022-10-18T15:59:36-04:00
2873345 BROWNSTEIN HYATT FARBER SCHRECK, LLP 441ca408-2937-421c-8fb9-831dec577a5f Q3 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 MEDIVANT HEALTHCARE 2022 third_quarter PHA Issues related to pharmaceutical manufacturing and supply       0 0 2022-10-18T20:00:07-04:00
2873353 BROWNSTEIN HYATT FARBER SCHRECK, LLP eb3e7bc2-9773-4ce8-bc0e-05c1c7b72b4f Q3 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 LILLY USA, LLC 2022 third_quarter PHA Issues related to the pharmaceutical industry H.R. 5376 - Inflation Reduction Act HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-18T20:20:57-04:00
2873527 THE KPM GROUP DC LLC 4db60422-db60-46f4-8c1f-1856ed7388e5 Q3 THE KPM GROUP DC LLC 401105372 CHIESI USA, INC. 2022 third_quarter PHA S. 4348 - FDASLA Act of 2022 H.R. 7667 - Food and Drug Amendments of 2022 H.R. 5376, the Inflation Reduction Act of 2022 Public Law 97-414, the Orphan Drug Act HOUSE OF REPRESENTATIVES,SENATE,White House Office 30000   0 0 2022-10-18T23:41:13-04:00
2873537 THE KPM GROUP DC LLC 21c64ace-88e1-4857-9a68-0af1fdd7703d Q3 THE KPM GROUP DC LLC 401105372 OVID THERAPEUTICS 2022 third_quarter PHA H.R. 5376, the Inflation Reduction Act of 2022 H.R. 4436, the Daniel Anderl Judicial Security and Privacy Act of 2021 HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-10-18T23:46:34-04:00
2873539 THE KPM GROUP DC LLC bf09a569-d2b1-4ea0-991b-95b1481e6bb3 Q3 THE KPM GROUP DC LLC 401105372 RARE DISEASE COMPANY COALITION 2022 third_quarter PHA S. 4348, the FDASLA Act of 2022 H.R. 7667, the Food and Drug Amendments of 2022 H.R. 5376, the Inflation Reduction Act of 2022 Public Law 97-414, the Orphan Drug Act HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-18T23:48:19-04:00
2873542 THE KPM GROUP DC LLC 8f79e0b8-bbc3-421b-812e-bc0796602972 Q3 THE KPM GROUP DC LLC 401105372 STEALTH BIOTHERAPEUTICS INC. 2022 third_quarter PHA Orphan drug incentives SENATE,White House Office 30000   0 0 2022-10-18T23:52:13-04:00
2873843 VAN SCOYOC ASSOCIATES 123900dc-cb51-45f2-858f-fcfc559f4fcc Q3 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2022 third_quarter PHA H.R.7900/S.4543, National Defense Authorization Act for Fiscal Year 2023, Temperature monitoring technology, Rapid Diagnostic Test Kits S.3799, PREVENT Pandemics Act, Rapid Diagnostic Test related issues HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-10-19T08:46:56-04:00
2874458 FAEGRE DRINKER BIDDLE & REATH LLP d3b37b8b-1845-4c1f-b6de-53f92e0549a1 Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 VERDE ENVIRONMENTAL TECHNOLOGIES, INC. 2022 third_quarter PHA Drug safety. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) 20000   0 0 2022-10-19T10:21:05-04:00
2874472 CARD & ASSOCIATES, LLC 8d091606-ebb4-4eed-879e-2c5579c18214 Q3 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2022 third_quarter PHA Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitoring federal appropriations for FY 2023 Access to telehealth Healthcare Extenders HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-10-19T10:23:08-04:00
2874529 FAEGRE DRINKER BIDDLE & REATH LLP cb22e4fe-e598-4ddf-b15b-2c295dd0297e Q3 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2022 third_quarter PHA Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act; S. 2796/H.R. 2985 Rural Opioid Abuse Prevention Act; H.R. 2355 Opioid Prescription Verification Act. Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE 30000   0 0 2022-10-19T10:30:30-04:00
2875053 RAMPY NORTHRUP LLC 445d6612-51cb-4b25-a855-68f6eca75988 Q3 RAMPY NORTHRUP LLC 401103289 ASTRAZENECA PHARMACEUTICALS LP 2022 third_quarter PHA Provide legislative and regulatory advice related to vaccine development, drug pricing, the 340B Drug Pricing Program, PDUFA Reauthorization, and clinical trial diversity; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.5030/S.2706, DIVERSE Trials Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.7559, Prescription Information Modernization Act of 2022; H.R.2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021. HOUSE OF REPRESENTATIVES 60000   0 0 2022-10-19T11:15:26-04:00
2875085 BURRELL INTERNATIONAL GROUP LLC 75aea893-97d4-4593-9877-623d916c88f5 Q3 BURRELL INTERNATIONAL GROUP LLC 401103483 ACER THERAPEUTICS 2022 third_quarter PHA COVID 19 therapeutics and Medical Countermeasures, Rare Disease and Re-purposed drugs; - FY22 Defense Appropriations for MCM Development HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-10-19T11:17:52-04:00
2875215 AARP d5d4c8cb-ba4f-47d3-99fc-1b1b324f68de Q3 AARP 1694 AARP 2022 third_quarter PHA P.L. 117-169, Inflation Reduction Act. S.4430, the Interagency Patent Coordination and Improvement Act of 2022. No bill number. Discussed allowing one time change in Medicare Part D plans. No bill number. Discussed cancer drug launch prices. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   4790000 0 0 2022-10-19T11:31:49-04:00
2875245 BURRELL INTERNATIONAL GROUP LLC 84e1e8d3-6865-4680-ae62-b99354d59923 Q3 BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2022 third_quarter PHA R&D Funding for Tonix Products and Services HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2022-10-19T11:34:11-04:00
2875609 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 375ea8bf-4e49-48eb-bb96-c91d6ac4c9cf Q3 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2022 third_quarter PHA COVID-19 Testing; Prescription Drugs; Insulin; Coverage of COVID-19 Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. The Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, by Sen. Jeanne Shaheen (D-NH) and Sen. Susan Collins (R-ME). Increases measures to encourage insulin manufacturers to reduce list prices, while extending patient protections that will foster competition and broader access to insulin products. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   130000 0 0 2022-10-19T12:09:29-04:00
2875653 GUIDEWELL MUTUAL HOLDING CORPORATION bb3e3ea2-a2d8-4e7f-b294-6b5306cb4985 Q3 GUIDEWELL MUTUAL HOLDING CORPORATION 401103191 GUIDEWELL MUTUAL HOLDING CORPORATION 2022 third_quarter PHA COVID-19 Testing; Prescription Drugs; Insulin; Coverage of COVID-19 Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. The Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, by Sen. Jeanne Shaheen (D-NH) and Sen. Susan Collins (R-ME). Increases measures to encourage insulin manufacturers to reduce list prices, while extending patient protections that will foster competition and broader access to insulin products. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 0 2022-10-19T12:13:43-04:00
2875761 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 4363dd4e-ea8f-403d-9a52-11bc93fda5f7 Q3 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 400270236 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 2022 third_quarter PHA PBM Drug Pricing Legislation HOUSE OF REPRESENTATIVES,SENATE   146000 0 0 2022-10-19T12:23:34-04:00
2875811 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 480cbf46-500e-4d32-8b69-075f0ce49e72 Q3 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 400270236 GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) 2022 third_quarter PHA PBM Drug Pricing Legislation HOUSE OF REPRESENTATIVES,SENATE   146000 0 0 2022-10-19T12:26:29-04:00
2876198 ALBERTSONS COMPANIES, INC. fe3a5ca7-62a8-4d94-a736-b07f33f31116 Q3 ALBERTSONS COMPANIES, INC. 401106186 ALBERTSONS COMPANIES, INC. 2022 third_quarter PHA Issues related to workforce, pharmacy services, nutrition and food production, processing and labeling. HOUSE OF REPRESENTATIVES,SENATE   410000 0 0 2022-10-19T12:46:01-04:00
2876231 BUCHANAN INGERSOLL & ROONEY PC 14ae9924-11ba-4bb2-8f01-0f99d76d96fe Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 ALLAY THERAPEUTICS 2022 third_quarter PHA Develop and execute a government relations strategy relating to Allay Therapeutics agenda and new drug application (NDA). Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-10-19T12:48:30-04:00
2876305 BUCHANAN INGERSOLL & ROONEY PC fcd7d6d6-c578-4fa8-b0a9-9b67ea709342 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 FERA PHARMACEUTICALS, LLC 2022 third_quarter PHA Strategy development and implementation of federal government relations initiatives relating to phospholine iodide issues with the Food and Drug Administration and Centers for Medicare and Medicaid Services. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-10-19T12:54:30-04:00
2876363 BUCHANAN INGERSOLL & ROONEY PC 5588bb43-0f53-48a6-a19d-5190d217f840 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 GENERIC ANIMAL DRUG ALLIANCE 2022 third_quarter PHA Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 8857, the Generic Animal Drug Advancement Act, all provisions Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-10-19T12:58:30-04:00
2876445 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES e8f0fa77-18ca-4e0e-bb06-cf7dbc10e81f Q3 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 2321 AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES 2022 third_quarter PHA Lower Prescription Drug Prices SENATE   470000 0 0 2022-10-19T13:02:47-04:00
2876569 TARPLIN, DOWNS & YOUNG, LLC 010fcfde-97fb-4657-9e08-04f645128d58 Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2022 third_quarter PHA Opioid abuse - general issues related to opioid abuse and access to medication assisted treatment; issues related to ARCOS data and suspicious order record requirements and reporting HR 768 Block, Report, and Suspended Suspicious Shipments Act of 2021 Importation of Prescription Drugs (HR 832, HR 2181, S 259, S 920, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-10-19T13:17:56-04:00
2876763 MEHLMAN CONSULTING, INC. f8f34c3e-8c66-4d5f-98aa-4e10c8c6eaa5 Q3 MEHLMAN CONSULTING, INC. 284950 MARIPOSA HEALTH, INC. (ON BEHALF OF PLUME) 2022 third_quarter PHA Issues related to tele-health. Ryan Haight Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-10-19T13:32:20-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2529.174ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API